Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

相似書籍

• Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies
  由: Savona, Michael R., et al.
  出版: (2018)
• Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
  由: Cogle, Christopher R., et al.
  出版: (2015)
• Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
  由: Garcia-Manero, G, et al.
  出版: (2016)
• Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
  由: Garcia-Manero, Guillermo, et al.
  出版: (2021)
• Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
  由: Garcia-Manero, Guillermo, et al.
  出版: (2016)